Search research articles
Contact Us
Filters
Showing results (1-10 of 28) with videos related to
Page
of 3
Sort By:
International Journal of Cancer
|
April 19, 2011
Farnesylthiosalicylic acid (salirasib) inhibits Rheb in TSC2-null ELT3 cells: a potential treatment for lymphangioleiomyomatosis
Victoria Makovski, Roni Haklai, Yoel Kloog
Journal of Pharmaceutical Sciences
|
July 13, 2010
Composite fiber structures with antiproliferative agents exhibit advantageous drug delivery and cell growth inhibition in vitro
Amir Kraitzer, Yoel Kloog, Roni Haklai, et al.
Methods in Enzymology
|
April 1, 2008
The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer
Barak Rotblat, Marcello Ehrlich, Roni Haklai, et al.
The Journal of Biological Chemistry
|
June 19, 2004
Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase activity
Galit Elad-Sfadia, Roni Haklai, Eyal Balan, et al.
Cancer Chemotherapy and Pharmacology
|
October 3, 2007
Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice
Roni Haklai, Galit Elad-Sfadia, Yaakov Egozi, et al.
The Enzymes
|
July 19, 2014
Ras chaperones: new targets for cancer and immunotherapy
Yoel Kloog, Galit Elad-Sfadia, Roni Haklai, et al.
Oncotarget
|
March 27, 2013
Growth of poorly differentiated endometrial carcinoma is inhibited by combined action of medroxyprogesterone acetate and the Ras inhibitor Salirasib
Raya Faigenbaum, Roni Haklai, Gilad Ben-Baruch, et al.
Cellular Signalling
|
February 11, 2026
Oncogenic crosstalk between ErbB2, nucleolin and Ras
Gal Zysman, Adva Kochavi, Roni Haklai, et al.
Cancer Research
|
February 21, 2006
Ras and its signals diffuse through the cell on randomly moving nanoparticles
Barak Rotblat, Ofer Yizhar, Roni Haklai, et al.
Journal of Medicinal Chemistry
|
December 17, 2008
New derivatives of farnesylthiosalicylic acid (salirasib) for cancer treatment: farnesylthiosalicylamide inhibits tumor growth in nude mice models
Liat Goldberg, Roni Haklai, Victor Bauer, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 28) with videos related to
Sort By:
Page
of 3
International Journal of Cancer
|
April 19, 2011
Farnesylthiosalicylic acid (salirasib) inhibits Rheb in TSC2-null ELT3 cells: a potential treatment for lymphangioleiomyomatosis
Victoria Makovski, Roni Haklai, Yoel Kloog
Journal of Pharmaceutical Sciences
|
July 13, 2010
Composite fiber structures with antiproliferative agents exhibit advantageous drug delivery and cell growth inhibition in vitro
Amir Kraitzer, Yoel Kloog, Roni Haklai, et al.
Methods in Enzymology
|
April 1, 2008
The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer
Barak Rotblat, Marcello Ehrlich, Roni Haklai, et al.
The Journal of Biological Chemistry
|
June 19, 2004
Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase activity
Galit Elad-Sfadia, Roni Haklai, Eyal Balan, et al.
Cancer Chemotherapy and Pharmacology
|
October 3, 2007
Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice
Roni Haklai, Galit Elad-Sfadia, Yaakov Egozi, et al.
The Enzymes
|
July 19, 2014
Ras chaperones: new targets for cancer and immunotherapy
Yoel Kloog, Galit Elad-Sfadia, Roni Haklai, et al.
Oncotarget
|
March 27, 2013
Growth of poorly differentiated endometrial carcinoma is inhibited by combined action of medroxyprogesterone acetate and the Ras inhibitor Salirasib
Raya Faigenbaum, Roni Haklai, Gilad Ben-Baruch, et al.
Cellular Signalling
|
February 11, 2026
Oncogenic crosstalk between ErbB2, nucleolin and Ras
Gal Zysman, Adva Kochavi, Roni Haklai, et al.
Cancer Research
|
February 21, 2006
Ras and its signals diffuse through the cell on randomly moving nanoparticles
Barak Rotblat, Ofer Yizhar, Roni Haklai, et al.
Journal of Medicinal Chemistry
|
December 17, 2008
New derivatives of farnesylthiosalicylic acid (salirasib) for cancer treatment: farnesylthiosalicylamide inhibits tumor growth in nude mice models
Liat Goldberg, Roni Haklai, Victor Bauer, et al.
Page
of 3